RESTORE® HYPER study results published on Minerva Cardiology and Angiology journal
Cardionovum® announces that the HYPER Study results, featuring the innovative RESTORE® DEB, have been published online in the Minerva Cardiology and Angiology journal, with the article entitled "Procedural and one-year outcomes following drug-eluting stent and drug-coated balloon combination for the treatment of de novo diffuse coronary artery disease: the HYPER Study”.
The HYPER is a prospective, multicenter study including patients affected by de novo diffuse CAD treated with a hybrid approach from April 2019 to December 2020, having as primary endpoint the evaluation of the 1-year device-oriented composite endpoint (DoCE, cardiac death, target vessel myocardial infarction and ischemia-driven target lesion revascularization [ID-TLR]).
Notable improvements were observed in the final minimal lumen diameters, and significant reductions in final diameter stenosis were noted when compared to baseline values in both DES- and DCB-targeted segments. Moreover, procedural success was achieved in an impressive 96.2% of cases;
Results showed also that the 1-year DoCE rate was low at 3.7%, with all adverse events being characterized by ID-TLR.
This study not only highlights that the hybrid approach could be a safe and effective treatment option for the treatment of de novo diffuse CAD, but offers also a promising alternative to traditional treatment methods, with encouraging one-year outcomes and a focus on reducing the need for additional interventions.
The article is available on: Procedural and one-year outcomes following drug-eluting stent and drug-coated balloon combination for the treatment of de novo diffuse coronary artery disease: the HYPER Study - Minerva Cardiology and Angiology 2023 Sep 13 - Minerva Medica - Riviste